Advancing Antibody Therapeutics to the Clinic
The Oncology Stream at PEGS is back to share what is new in the fight against cancer, and the antibody developments that are leading the charge. Drug discovery in oncology has relied on antibodies as a tool to determine therapeutic success. Bispecific
antibodies and cell engagers, as well as antibody-drug conjugates are all utilized to improve targeted therapy and drug delivery. This year, we will look at how these impact the clinical journey from discovery to trials, whether as a
single agent or in combinations. We will investigate the role of the tumor microenvironment and microbiome, and what is next on the horizon in biologic development in oncology.
Antibodies for Cancer Therapy
Driving Clinical Success in Antibody-Drug Conjugates
Recommended Short Course:
SC1: CAR T Cell Therapy from A-Z
Instructor: Tara Arvedson, PhD, Executive Director, Oncology Research, Amgen, Inc.
Silvia C. Formenti, MD, Chairman & Professor, Radiation Oncology, Cornell University
Marjorie C. Green, PhD, Senior Vice President & Head, Late Stage Development, Seattle Genetics